CopyMark Law Group
4.9/5
Drawing for DIZAL

USPTO serial 90221395

DIZAL

Reviewed by CopyMark Law Group

Reg. 6890229Status 700Registered
Filing date
Status date
Registration date
Nov 1, 2022
Examiner
NEHMER, JASON ROBERT
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DIZAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Catherine M.C. Farrelly

Catherine M.C. Farrelly Frankfurt Kurnit Klein & Selz PC28 Liberty StreetNew York, NY 10005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Preparations for destroying noxious animals; antiseptics; bacterial culture mediums; bouillons for bacteriological cultures; media for bacteriological cultures; bacterial poisons; balsamic preparations for medical purposes; insecticides; medicinal preparations for the mouth to be applied in the form of capsules; pharmaceutical preparations for treatment of human illnesses, namely, anti-tumor treatment; chemico-pharmaceutical preparations for treatment of human illnesses, namely, anti-tumor treatment; collyrium; medicines for alleviating constipation; solutions for contact lenses; radiological contrast substances for medical purposes; depuratives for the body; digestives for pharmaceutical purposes; analgesics; drugs for medical purposes for treatment of human illnesses, namely, anti-tumor treatment; filled portable medicine cases, comprised of pharmaceuticals for treatment of human illnesses, namely, anti-tumor treatment; pharmaceutical preparations, namely, elixirs for anti-tumor treatment; mineral, bath and sodium salts for medical purposes; esters for pharmaceutical purposes; ethers for pharmaceutical purposes; fungicides; gelatine for medical purposes, namely, gelatin capsules sold empty; germicides; chewing gum for medical purposes; medicated lozenges for pharmaceutical purposes; cough pastilles for pharmaceutical purposes; rat poison; antibiotic, sunburn and anti-inflammatory ointments for pharmaceutical purposes; organotherapy preparations; opotherapy preparations; pharmaceutical preparations for skin care; herbal teas for medicinal purposes; cachets in the nature of capsules for medicinal preparations for the mouth for pharmaceutical purposes; first-aid boxes, filled; blood plasma; radioactive substances for medical purposes; tonics being pharmaceutical preparations for the treatment of human illnesses, namely, anti-tumor treatment; blood for medical purposes; sterilizing preparations; styptic preparations; aluminum acetates for pharmaceutical purposes; acids for pharmaceutical purposes; dietetic foods adapted for medical purposes; biological preparations for medical purposes for treatment of human illnesses; dietetic beverages adapted for medical purposes; crystallized rock sugar for medical purposes; candy for medical purposes; cellulose esters for pharmaceutical purposes; cellulose ethers for pharmaceutical purposes; by-products of the processing of cereals for dietetic or medical purposes; chemical preparations for pharmaceutical purposes for the treatment of human illnesses, namely, anti-tumor treatment; medicines for dental purposes; anti-allergic and pain reduction medicines for treatment of illnesses for human purposes; diagnostic preparations for medical purposes; medicinal drinks; petroleum jelly for medical purposes; isotopes for medical purposes; dietetic substances of low sugar and salt adapted for medical use; chemical preparations as medicines for medical purposes, namely, for anti-tumor treatment; chemical reagents for medical purposes for the treatment of human illnesses; contact lens cleaning preparations; enzymes for medical purposes; enzyme preparations for medical purposes; amino acids for medical purposes; antibiotics; bronchodilating preparations; medicinal hair growth preparations; adjuvants for medical purposes; stem cells for medical purposes; biological tissue cultures for medical purposes; medicated eye-washes; antioxidant pills for medical use; protein dietary supplements; reagent paper for medical purposes; pesticides; diagnostic biomarker reagents for medical purposes; phytotherapy preparations for medical purposes; pre-filled syringes of medicines for medical treatment purposes, namely, anti-tumor treatment; reagent paper for veterinary purposes; astringents for medical purposes; insecticidal veterinary washes; capsules made of dendrimer-based polymers for medicinal preparations for the mouth, for pharmaceuticals purposes; raw material drugs, namely, pharmaceuticals for anti-tumor treatment; Chinese medicine nostrum for the treatment of tumors in humans; pharmaceutical blood preparations, namely, a blood clotting aid and delivery system for use in human medicine; rubbing alcohol; agricultural fungicide; eye drops; insect killing preparations in the nature of pesticides; pharmaceutical preparation for application to the eye or intraocular surgery for the purpose of anti-tumor treatment; ophthalmic pharmaceutical products for anti-tumor treatment; ophthalmic preparations; candy for pharmaceutical purpose for treatment of the cough; bacteriological research preparation, namely, preparations of reports for anti-tumor treatment for medical purposes; bacterial preparations for medical purposes for researching of human illnesses; medical probiotic supplements; medical diagnosis reagent; vaccine preparations; contact lenses care solution; contact lens disinfectant; biological agents for the treatment of cancerACTIVENov 18, 2019
035Publicity consultation and agency services in the field of medicines; provision of goods sales information, namely, sales information about goods for anti-tumor treatment; retail store services featuring pharmaceutical, sanitary preparations and medical supplies; wholesale distributorships featuring pharmaceutical preparations, sanitary preparations, and medical supplies; retail store services and wholesale store services featuring pharmaceutical drugs; retail store services and wholesale store services featuring medicinal preparations; retail store services and wholesale store services featuring sanitary preparations; retail store services and wholesale store services featuring medical suppliesACTIVENov 18, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 1, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Nov 1, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 30, 2022SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 28, 2022FIXDELECTRONIC RECORD REVIEW COMPLETE—
Sep 23, 2022ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 20, 2022SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 18, 2022CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Sep 16, 2022SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 14, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 31, 2022IUAFUSE AMENDMENT FILED—
Aug 31, 2022EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 1, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 4, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 4, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 15, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 24, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 22, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 22, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 22, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 14, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 14, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 14, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 12, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 5, 2021PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Sep 16, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 11, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 10, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 10, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Sep 3, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 3, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 3, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 3, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 3, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 3, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 12, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Mar 12, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 12, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 3, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 2, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 2, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 1, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 22, 2021DOCKASSIGNED TO EXAMINER—
Nov 13, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Nov 12, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 2, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance